Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are efficacious pharmacological therapies for T2D, which lead to a reduction in plasma glucose levels and induce weight loss without increasing the associated risk of hypoglycemia (Nauck, 2016). This evidence concerns the gene GCG and Hypoglycemia.